TD Cowen analyst Charles Rhyee raised the firm’s price target on Cardinal Health to $109 from $96 and keeps a Market Perform rating on the shares. The firm thinks the 2H Pharma EBIT guide could prove conservative given continued strength in pharma utilization environment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CAH:
- Cardinal Health Executives to Discuss Quarterly Results and Outlook
- Cardinal Health raises FY24 EPS view to $7.20 to $7.35 from $6.75-$7.00
- Cardinal Health reports Q2 EPS $1.82, consensus $1.60
- Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook
- Notable companies reporting before tomorrow’s open
